Inclusion Body Myositis patients have no approved treatment options despite progressive muscle deterioration

Patients with inclusion body myositis (IBM) suffer from worsening muscle weakness with zero FDA-approved drugs available, forcing them to endure progressive disability without therapeutic options. Current clinical trials fail to show efficacy across patient populations, leaving physicians and patients desperate for any viable treatment. The lack of approved therapeutics means patients watch their condition deteriorate while pharmaceutical companies struggle to develop effective interventions.